The key factors propelling the growth of this market are rising government funding and growth in the number of genomics projects, high prevalence of infectious diseases and cancer, technological advancements, increasing production of genetically modified crops, and growing application areas of genomics.
According to research report the global genome editing market is projected to reach $6.28 billion by 2022 from $3.19 billion in 2017, at a CAGR of 14.5% during the forecast period.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=231037000
•Based
on technology, the genome editing market is segmented into CRISPR,
TALEN, ZFN, antisense, and other technologies (PiggyBac, Flp-In, Adenine
Base Editor (ADE), and Jump-In). The CRISPR segment is expected to
register the highest growth during the forecast period.
•The global
genome editing market, by application, is segmented into cell line
engineering, genetic engineering, and other applications (diagnostics
and therapeutics). The cell line engineering segment is estimated to
register the highest growth rate during the forecast period.
•Based
on end user, the global genome engineering market is segmented into
biotechnology & pharmaceutical companies, academic & government
research institutes, and contract research organizations.
Recent Developments:
>
In 2020, New England Biolabs collaborated with ERS Genomics to develop
and commercialize CRISPR gene editing tools and reagents
> In
2019, Thermo Fisher Scientific acquired Brammer Bio to access Brammer
Bio’s expertise in manufacturing vectors for genes and cell therapies
>
In 2019, Horizon Discovery launched predesigned synthetic single-guide
RNA (sgRNA) to aid researchers in achieving targeted gene knockouts and
conducting DNA-gene free editing
The major companies in the genome editing market include Thermo Fisher Scientific (US), Merck (Germany), Horizon Discovery Limited (UK), Lonza (Switzerland), GenScript (US), Eurofins Scientific (Luxembourg), Sangamo Therapeutics (US), Editas Medicine (US), CRISPR Therapeutics (Switzerland), Precision Biosciences (US), Oxford Genetics (UK), Intellia Therapeutics (US), Synthego (US) & Others
Get Report Sample: https://www.marketsandmarkets.com/requestsampleNew.asp?id=231037000
The Genome Engineering Market is divided into four major regions—North America, Europe, Asia Pacific, and the Rest of the World (RoW). In 2019, North America accounted for the largest share of the global genome editing market. The market in the Asia Pacific is estimated to grow at the highest CAGR during the forecast period, primarily due to increasing investments in research and the application of gene synthesis for genetic engineering in cells, tissues, and organisms.
